Avalon GloboCare shares surge 32.73% after hours on FDA KetoAir registration renewal and planned Q2 2026 B2B/B2C launch via AI platform.

Avalon GloboCare Corp. surged 32.73% in after-hours trading following the announcement of FDA registration renewal for its KetoAir™ breathalyzer and plans to launch the device in Q2 2026 via its AI-powered Catch-Up™ SaaS platform. The FDA renewal ensures continued U.S. market compliance for the Class I medical device, which measures breath acetone to monitor ketogenic health. The company outlined a dual B2B/B2C strategy using Catch-Up™ to scale marketing, distribution, and digital engagement, signaling expanded commercial potential. The announcement reinforced confidence in Avalon’s ability to leverage its AI and diagnostic technologies to drive growth in both enterprise and consumer markets, aligning with the stock’s sharp post-market rally.